Avoidant personality disorder

disease

On this page

Also known as anxious personality disorder

Summary

Avoidant personality disorder (MONDO:0002027) is a disease and 5 clinical trials. Top therapeutic interventions include duloxetine. A subtype of personality disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	avoidant personality disorder
Mondo ID	MONDO:0002027
DOID	DOID:1509
ICD-10-CM	F60.6
ICD-11	429615620
NCIT	C92636
SNOMED CT	231528008
UMLS	C0004444
MedGen	13985
Is cancer (heuristic)	no

Also known as: anxious personality disorder

Disease family

This is a subtype of personality disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › personality disorder › avoidant personality disorder

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	5

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07341438	Not specified	RECRUITING	Physical Activity in the Management of Personality Disorders
NCT00247234	Not specified	COMPLETED	Effectiveness of Group Based Schema Therapy in the Treatment of Personality Disorders
NCT02465697	Not specified	COMPLETED	Changes in the Brain as Borderline Patients Learn to Regulate Their Emotions
NCT03833531	Not specified	COMPLETED	Effectiveness of PTSD-treatment Compared to Integrated PTSD-PD-treatment in Adult Patients With Comorbid PTSD and CPD
NCT05930912	Not specified	UNKNOWN	Psychiatric Orders in Psychoanalytic Treatment of ASD

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DULOXETINE	4	1

Drugs: Duloxetine